Alof G. Dallenga - Publications

Progression of hearing loss after LINAC-based stereotactic radiotherapy for vestibular schwannoma is associated with cochlear dose, not with pre-treatment hearing level.

Journal: Radiation oncology (London, England)

Published: September 27, 2018

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.

Journal: European journal of endocrinology

Published: April 24, 2018

A novel noninstrumented surgical approach for foramen reconstruction for isthmic spondylolisthesis in patients with radiculopathy: preliminary clinical and radiographic outcomes.

Journal: Neurosurgical focus

Published: January 02, 2018

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

Journal: The Journal of clinical endocrinology and metabolism

Published: September 11, 2017

Very long-term sequelae of craniopharyngioma.

Journal: European journal of endocrinology

Published: January 19, 2017

Identifying at diagnosis the vestibular schwannomas at low risk of growth in a long-term retrospective cohort.

Journal: Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery

Published: April 11, 2016

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Journal: Neuroendocrinology

Published: February 03, 2016

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 18, 2014